文献速递心外重症与机械循环支持

STS Intermacs数据库年度报告:适应证、结局与科学合作演变

The Society of Thoracic Surgeons Intermacs Database Annual Report: Evolving Indications, Outcomes, and Scientific Partnerships.
PubMed 文献 · Ann Thorac Surg · 2019-01-01

该报告总结了2006年6月23日至2017年12月31日期间≥19岁接受持久机械循环支持(MCS)植入的患者的结局。共25,145例成人患者,其中18,539例(74%)接受连续流左心室辅助装置(CF LVAD)。CF LVAD患者平均年龄57±1岁,26%列为移植候选,51%术前处于心源性休克。CF LVAD支持的中位时间为20个月(31,563患者年),1年生存率83%,5年生存率46%。

要点

  • CF LVAD患者1年生存率83%,5年生存率46%。
  • 离心泵与轴流泵1年生存率分别为85%和84%。
  • 需同期RVAD辅助者1年和5年生存率分别为58%和28%。

核心结论

  • 随着MCS的演变,患者表型和结局也在随时间变化。
  • CF LVAD支持越来越多地用于病情较轻的患者表型,更多患者以目的地治疗为指征。
  • 平均生存期正接近5年,但不良事件特别是神经系统事件仍对CF LVAD支持的成功产生不利影响。

研究设计与样本

  • Intermacs数据库年度报告,总结2006年6月23日至2017年12月31日期间≥19岁接受持久MCS植入的患者结局。
  • 共报告25,145例成人MCS患者,其中18,539例(74%)接受CF LVAD,667例(2.6%)接受CF LVAD联合RVAD,339例(1.3%)接受全人工心脏,20例(0.07%)接受孤立RVAD。
  • CF LVAD分析按轴流和离心流配置分层;生存分析限于2012至2016年期间植入的孤立CF LVAD。

主要发现

  • CF LVAD患者平均年龄57±1岁,26%列为移植候选,51%术前处于心源性休克(profile 1至2)。
  • CF LVAD包括14,527例轴流(78%)和4,012例离心流(22%)装置。
  • 患者表型随时间演变:profile 3从2006至2011年的26%增至2012至2016年的35%,profile 2从40%降至35%,目的地治疗指征从29%增至48%。
  • 2017年离心流植入(51%)接近轴流装置(49%)。
  • CF LVAD支持中位时间20个月(31,563患者年);孤立CF LVAD的1年生存率83%,5年生存率46%。

临床怎么用

  • CF LVAD支持用于病情较轻患者和目的地治疗指征逐渐增多,临床决策需考虑患者表型演变。
  • 离心流与轴流装置生存率相近,但离心流卒中风险较高、消化道出血风险较低,装置选择需权衡不良事件特征。
  • 需同期RVAD辅助者生存率显著较低,应加强风险评估和术后管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs), a joint effort among the National Heart, Lung, and Blood Institute, the Food and Drug Administration, the Centers for Medicare and Medicaid Services, and others, was established in 2005 at the University of Alabama at Birmingham. The registry examined clinical outcomes and quality-of-life metrics of patients who received an Food and Drug Administration-approved durable mechanical circulatory support (MCS) device to treat advanced heart failure. On January 1, 2018, the Intermacs Database became part of The Society of Thoracic Surgeons National Database, providing additional resources for quality assessment and improvement and scientific advancement. METHODS: The Intermacs Database Annual Report summarizes outcomes in patients (≥19 years of age) who underwent durable MCS implant between June 23, 2006, and December 31, 2017. Outcomes are presented for patients who underwent isolated continuous flow left ventricular assist device (CF LVAD) support, CF LVAD support with concomitant right ventricular assist device (RVAD) implant, or total artificial heart implant. Analyses of patients with CF LVADs are stratified by axial flow and centrifugal flow configurations. Because of the association of era with outcomes, the survival analyses are restricted to isolated CF LVADs implanted in the 2012 to 2016 era. RESULTS: There were 25,145 adult patients with MCS reported to Intermacs, of whom 18,539 (74%) received CF LVADs, 667 (2.6%) had an RVAD with CF LVAD, 339 received a total artificial heart (1.3%), and 20 (0.07%) received an isolated RVAD. Of the CF LVADs, mean age was 57 ± 1 years, 26% were listed for transplantation, and 51% were in cardiogenic shock (profile 1 to 2) preoperatively. CF LVADs included 14,527 axial flow (78%) and 4,012 centrifugal flow (22%) devices. Intermacs patient phenotype has evolved over time to include more patients with profile 3 (26% in 2006 to 2011 versus 35% in 2012 to 2016) and fewer patients with profile 2 (40% versus 35%), patients with better markers of preoperative renal and hepatic function, and more patients who received implants for destination therapy (29% versus 48%) indication. In 2017, centrifugal flow implants (51%) approximated that of axial flow devices (49%). Mean CF LVAD support duration was 20 months (31,563 patient-years). One-year survival for isolated CF LVADs was 83% and 5-year survival was 46%. One-year survivals for centrifugal versus axial flow devices were 85% and 84%, respectively. Patients who required concomitant RVAD support had 1- and 5-year survivals of 58% and 28%, respectively. Freedom from all-cause readmission was 70% at 1 month and 20% at 1 year. At 1 year, stroke occurred in 20% of patients on centrifugal flow and 13% of patients on axial flow support (p < 0.001), gastrointestinal bleeding affected 20% of patients with centrifugal flow devices and 25% of patients with axial flow devices (p < 0.001), and pump-related infection occurred in 28% of patients with centrifugal flow devices versus 25% of patients with axial flow devices (p = 0.01). Neurologic dysfunction (19% of deaths) and multisystem organ dysfunction (15%) were the most common causes of death. CONCLUSIONS: With the evolution of MCS, patient phenotype and outcomes are also changing over time. CF LVAD support is increasingly being used in the less ill patient phenotype and more patients are supported for destination therapy. Mean survival is now approaching 5 years, but adverse events, especially neurologic events, continue to have a detrimental impact on the success of CF LVAD support.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Kormos RL, Cowger J, Pagani FD, et al. The Society of Thoracic Surgeons Intermacs Database Annual Report: Evolving Indications, Outcomes, and Scientific Partnerships. Ann Thorac Surg. 2019. PMID: 30691584. doi:10.1016/j.athoracsur.2018.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。